Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.
about
Progress and perspectives on targeting nanoparticles for brain drug delivery.Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatmentPI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancerTargeted Therapies for Brain Metastases from Breast CancerBreast cancer brain metastases: biology and new clinical perspectivesBreast Cancer Brain Metastases: Clonal Evolution in Clinical Context.Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.Preparation and Identification of HER2 Radioactive Ligands and Imaging Study of Breast Cancer-Bearing Nude Mice.Approaches for optimal drug development and clinical trial design for breast cancer brain metastasis.Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner.Lapatinib for the treatment of breast cancer in the People's Republic of China.Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancerEmerging strategies for treating brain metastases from breast cancer.The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in GlioblastomaLapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.Unsanctifying the sanctuary: challenges and opportunities with brain metastases.Understanding Heterogeneity and Permeability of Brain Metastases in Murine Models of HER2-Positive Breast Cancer Through Magnetic Resonance Imaging: Implications for Detection and Therapy.Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeuticsLapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress.Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by LapatinibExamination of blood-brain barrier (BBB) integrity in a mouse brain tumor modelCharacterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer.Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.Evaluating Changes to Blood-Brain Barrier Integrity in Brain Metastasis over Time and after Radiation Treatment.SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases.P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer modelO-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.Targeted therapies in brain metastases.Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans.Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2.Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells.Optimal management of brain metastases from breast cancer. Issues and considerations.Targeted delivery of nano-therapeutics for major disorders of the central nervous system.Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts.The role of systemic and targeted therapies in brain metastases.
P2860
Q26740580-7235A0BC-F81B-4760-AAC5-70071792D50CQ26751008-EF2FE023-D8E5-4F85-ADC3-96696AB6A237Q27006181-1D7D2E53-18D9-4596-B2B4-9525769F41CDQ28068154-D8F8A0FA-8CF1-48B7-8996-12496A22EF01Q28078998-D144EC96-026C-4100-B6F5-CD9FE06FB925Q30238959-6A37776A-1590-469F-9D1E-41C368862A6FQ30450038-F330796F-06B6-4632-8B57-9BC84CD711BAQ33591658-7B8167A4-AEFB-47E2-9E86-AF40FAB7311FQ33736383-97C37DCD-F655-416A-A4CB-2D7D42FCA4B4Q33891408-FFEC99C0-2BDA-45DD-BE9A-828320B98132Q33909294-865E545C-42E3-45A9-9037-1D7798C2BA9CQ34016491-16A1BB74-2520-4157-9A76-6AC76E10148AQ34572719-FE00A08D-8405-4E0A-B7FD-8973F6C2134AQ34582560-9F99FC97-837A-464B-A8E5-818EEF45A57AQ34886764-23158100-9F75-4DC2-86BC-FB81D1FD8FCDQ35023917-FFC5D62F-7A37-4AFE-975C-BACC8CE02E71Q35075446-71080432-D9C9-4EA1-ABFF-E06361A81B12Q35463482-4881F912-611D-4206-8AFB-3280687E8321Q35582767-54EE1497-B357-4171-9B6B-36B46FB63606Q35788631-D25D4492-3603-412A-875D-4A3918F529BDQ35804288-CDCFD8D1-46AA-49BF-A56E-5A36C87B1BCDQ35913109-D7CC7A19-9C6F-4614-900F-E82A47F9B728Q36396421-D81503EF-EEDE-486D-BB11-3ABA91F78019Q36412836-055535E4-1AD2-4FF1-85C5-E28FFBDC48FBQ36482601-8E9A7C72-F0D5-412F-B4DA-5C3D51680AE3Q36562978-D7983093-4ADE-4D81-8BAD-4A1BD44D5942Q36721489-54D10361-55EB-4667-B7DA-2FFA22C97E7BQ36923104-DE32019F-853A-4698-986D-81A62E06B79EQ37004561-79C6D7AF-7345-4EB4-9FD8-395F0533FB65Q37193756-729B0CD6-6536-4867-BFE2-76CE8EBD78A2Q37276052-CEF553A6-6F17-4F22-B0F0-3EA05734FAB9Q37432524-72CF9ACE-8CFE-41C0-8BAA-E1D468783262Q37491460-9107F3D9-72B1-45DD-A723-415EBB062099Q37498669-7A2C6FB0-899B-4583-9838-D53FFBCA2CD0Q37554942-431614A4-CDEE-4833-8D02-C00275B34776Q37694756-B2A62D81-5C94-475E-BD6D-D336481B26C2Q38067340-1DDB8894-8651-428F-93CF-C094E4AD3BF6Q38116765-A0B6DA5E-8814-4619-A963-AEF4CE26FAE3Q38155202-BDD7821E-CFE0-4302-AA4B-3C597EAD30B2Q38168919-8F22BB70-4AE1-434F-A8F1-A755E0F6A188
P2860
Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Lapatinib distribution in HER2 ...... n metastases of breast cancer.
@ast
Lapatinib distribution in HER2 ...... n metastases of breast cancer.
@en
type
label
Lapatinib distribution in HER2 ...... n metastases of breast cancer.
@ast
Lapatinib distribution in HER2 ...... n metastases of breast cancer.
@en
prefLabel
Lapatinib distribution in HER2 ...... n metastases of breast cancer.
@ast
Lapatinib distribution in HER2 ...... n metastases of breast cancer.
@en
P2093
P2860
P1476
Lapatinib distribution in HER2 ...... in metastases of breast cancer
@en
P2093
Brunilde Gril
Diane Palmieri
Helen R Thorsheim
Julie Lockman
Kunal S Taskar
Patricia S Steeg
Paul R Lockman
Quentin R Smith
Rajendar K Mittapalli
P2860
P304
P356
10.1007/S11095-011-0601-8
P577
2011-10-20T00:00:00Z